

#18

PTO/SB/004(10-01)

Approved for use through 10/31/2002. OMB 651-0031  
US Patent & Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

JUN 02 2003

Sheet 1 of 6

Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1641
Examiner Name	Sullivan, Daniel

Attorney Docket No: 875.032US1

TECH CENTER 16012900  
JUN 10 2003

RECEIVED

## US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
DS	US-5,604,090	02/18/1997	Alexander, Ian E., et al.	435	5	06/06/1994
DS	US-5,691,176	11/25/1997	Lebkowski, J. S., et al.	435	172.3	06/02/1995
DS	US-5,834,182	11/10/1998	Alexander, Ian E., et al.	435	5	02/25/1997
DS	US-6,083,702	07/04/2000	Mitchell, L. G., et al.	435	6	08/13/1998
DS	US-6,200,560	03/13/2001	Couto, L. B., et al.	424	93.2	12/22/1999

Already of record (#10)

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T <sup>2</sup>
DS	WO-94/13788 ✓	12/04/1992	Coruzzi, Laura A., et al.	C12N	7/01	
DS	WO-95/07351 ✓	09/10/1993	Jarrell, Kevin A.	C12N	15/10	
DS	WO-97/22250 ✓	12/13/1996	Mitchell, Lloyd G.	A01N	43/04	
DS	WO-98/09657 ✓	09/06/1996	Wilson, James M., et al.	A61K	48/00	

## OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DS		"(S)-(+)-Camptothecin; 4-Ethyl-4-hydroxy-1H-pyrano[3', 4': 6,7] indolizino [1,2- b] quinoline-3, 14 (4H, 12H) dione", <u>Calbiochem</u> , Camptothecin, Camptotheca acuminata, (October 2, 2000), 1-2	
DS		"Adriamycin; 14-Hydroxydaunomycin, HCl", <u>Calbiochem</u> , Doxorubicin, Hydrochloride, Catalog Number 324380, (October 21, 1998), 1-2	
DS		"Aminoglycoside antibiotic. Inhibits myeloperoxidase-dependent oxidant cell injury", <u>Calbiochem</u> , Tobramycin, Free Base, Catalog Number 614005, (August 26, 1999), 1	
DS		"Cancer Research", <u>Contribution to Society</u> , <a href="http://www.bikaken.or.jp/mcrf_e/contribution">http://www.bikaken.or.jp/mcrf_e/contribution</a> , (December 4, 2000), 2 pages	
DS		"Carbobenzoxymethyl-L-leucyl-L-leucinal", <u>Calbiochem</u> , MG-132, Catalog Number 474790, (October 15, 1999), 1-2	
DS		"Drugs for Selection of Genetic Markers Reagents for positive and negative selection of Genes involved in Nucleotide Metabolism", <u>Calbiochem</u> , (March 2002), 6 pages	
DS		"EPA; 20:5 w-3; 5,8, 11, 14, 17-Eicosapentaenoic Acid", <u>Calbiochem</u> , Eicosapentaenoic Acid, Catalog Number 324875, (December 7, 1998), 1-2	
DS		"Epoxomicin- a potent and selective proteasome inhibitor", <u>Affiniti Research Products Limited</u> , 2 pages	
DS		"LDP-341", <u>Millennium Pharmaceuticals</u> , <a href="http://www.biospace.com/ct/detail.cfm?ClinicalID=266404">http://www.biospace.com/ct/detail.cfm?ClinicalID=266404</a> , 1 page	✓
DS		"Mevinolin; MK-803", <u>Calbiochem</u> , Lovastatin, Catalog Number 438185, (June 29, 2001), 1-2	✓

EXAMINER

DSullivan

DATE CONSIDERED

7/25/03

Substitute Disclosure Statement Form (PTO-1449)


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1641
Examiner Name	Sullivan, Daniel

Sheet 2 of 6

Attorney Docket No: 875.032US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DS		"MK-733", <u>Calbiochem</u> , Simvastatin, Catalog Number 567020, (October 25, 2001), 2	✓
DS		"Polymer Vectors Endosomal release and cytoplasmic delivery", <u>Endosomal Release</u> , <a href="http://web.bham.ac.uk/can4psd4/nonviral/endosome.html">http://web.bham.ac.uk/can4psd4/nonviral/endosome.html</a> , (June 3, 2001), 1	✓
DS		"Product Data Sheet", <u>Moravek Biochemicals, Inc.</u> , M-1535, Ritonavir, (July 12, 2001), 1 page	✓
DS		"Product Information", <u>Sigma</u> , Cyclosporin A, Sigma Product No. C3662, (October 28, 1996), 3 pages	✓
DS		"Product Information", <u>Sigma</u> , Bleomycin Sulfate, Sigma Prod. No. B5507, (November 25, 1996), 2 pages	✓
DS		"Proteasome Inhibitors", <u>Peptides International, Inc.</u> , (April 16, 2001), 1-2	✓
DS		"Tannic Acid, A.C.S. reagent", <u>Sigma</u> , <a href="http://www.sigma-aldrich.com/sacatalog.nsf/productlookup/Aldrich403040?OpenDocument">www.sigma-aldrich.com/sacatalog.nsf/productlookup/Aldrich403040?OpenDocument</a> , 1 page	✓
DS		ADAMS, JULIAN, et al., "Novel Inhibitors of the Proteasome and Their Therapeutic Use in Inflammation", <u>Annual Reports in Medicinal Chemistry</u> , Academic Press, Inc., (1996), 279-288	✓
DS		ANDRE, PATRICE, et al., "An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses", <u>Proc. National Academy of Science USA</u> , vol. 95, (October 1998), 13120-13124	✓
DS		BANERJEE, D., et al., "The treatment of respiratory pseudomonas infection in cystic fibrosis: What drug and which way?", <u>Drugs</u> , 60(5), abstract, (November 2000), 1 page	✓
DS		BIES, J., et al., "Oncogenic activation of c-Myb by Carboxyl-Terminal truncation leads to Decreased Proteolysis by the Ubiquitin-26S proteasome pathway", <u>Oncogene</u> , vol. 14, no. 2, Abstract, (January 16, 1997), 1 page	✓
DS		BOKKALA, SHAILA, et al., "Angiotensin II-induced Down-regulation of Inositol Trisphosphate Receptors in WB Rat Liver Epithelial Cells", <u>Journal of Biological Chemistry</u> , vol. 272, no. 19, (May 9, 1997), 12454-12461	✓
DS		BONACORSI, STEPHANE, et al., "Comparative In Vitro Activities of Meropenem, Imipenem, Temocillin, Piperacillin, and Ceftazidime in Combination with Tobramycin, Rifampin, or Ciprofloxacin against Burkholderia cepacia Isolates from Patients with Cystic Fibrosis", <u>Antimicrobial Agents and Chemotherapy</u> , vol. 43, no. 2, (February 1999), 213-217	✓
DS		BRAND, STEPHEN, et al., "Role of the Proteasome in Rat Indomethacin-Induced Gastropathy", <u>Gastroenterology</u> , vol. 116, no. 4, (1999), 865-873	✓
DS		BRAVO, LAURA, "Polyphenols: Chemistry, Dietary Sources, Metabolism and Nutritional Significance", <u>Nutrition Reviews</u> , vol. 56, no. 11, (November 1998), 317-333	✓
DS		BUGG, C., et al., "SRI6975 Increases Adenovirus Mediated Gene Transfer Through the Apical Surface of Polarized MDCK Cell Monolayers", <u>Cystic Fibrosis</u>	✓

EXAMINER

DATE CONSIDERED

7/25/03

Substitute Disclosure Statement Form (PTO-1449)


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1641
Examiner Name	Sullivan, Daniel

Sheet 3 of 6

Attorney Docket No: 875.032US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Foundation: 2000 North American CF Conference, (November 2000),1	
DS		CANTIN, ANDRE M., et al., "Aerosolized Prolastin Suppresses Bacterial Proliferation in a Model of Chronic Pseudomonas aeruginosa Lung Infection", <u>American Journal of Respiratory and Critical Care Medicine</u> , vol. 160, (1999),1130-1135	✓
DS		CHUNG, KING-THOM, et al., "Tannis and Human Health: A Review", <u>Critical Reviews in Food Science and Nutrition</u> , 38(6), (1998),421-464	✓
DS		DESAI, SHYAMAL, et al., "Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin", <u>Journal of Biological Chemistry</u> , (September 26, 1997),24159-24164	✓
Already referred of (#7)		<del>DUAN, DONGSHENG, et al., "Circular intermediates of recombinant adenovirus-associated virus having defined structural characteristics responsible for long-term episomal persistence in muscle tissue", <u>J. of Virology</u>, 72 (11), (Nov. 1998), pp. 8568-8577.</del>	
PC		FAYADAT, LAURENCE, et al., "Degradation of Human Thyroperoxidase in the Endoplasmic Reticulum Involves Two Different Pathways Depending on the Folding State of the Protein", <u>Journal of Biological Chemistry</u> , vol. 275, no. 21, (May 26, 2000),15948-15954	✓
DS		FENTEANY, GABRIEL, et al., "Lactacystin, Proteasome Function, and Cell Fate", <u>Journal of Biological Chemistry</u> , vol. 273, no. 15, (April 10, 1998),8545-8548	✓
DS		FIGUEIREDO-PEREIRA, MARIA, et al., "The Antitumor Drug Aclacinomycin A, Which Inhibits the Degradation of Ubiquitinated Proteins, Shows Selectivity for the Chymotrypsin-like Activity of the Bovine Pituitary 20 S Proteasome", <u>Journal of Biological Chemistry</u> , (July 12, 1996),16455-16459	✓
DS		GABIZON, ALBERTO, "Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals", <u>Advanced Drug Delivery Reviews</u> , (1997),337-344	✓
DS		GABIZON, ALBERTO, et al., "Preclinical Studies with Doxorubicin Encapsulated in Polyethyleneglycol-Coated Liposomes", <u>Journal of Liposome Research</u> , 3(3), (1993),517-528	✓
DS		GARBER, KEN, "Taking Garbage In, Taking Cancer Out?", <u>Science</u> , vol. 295, (January 25, 2002),612-613	✓
DS		HASEGAWA, S., et al., "Microtubule involvement in the intracellular dynamics for gene transfection mediated by cationic liposomes", <u>Gene Therapy</u> , vol. 8, (2001),1669-1673	✓
DS		HONG, J., et al., "Identification of SRI6975, A Compound that Enhances Adenovirus-Mediated Gene Expression in Polarized Epithelial Cells", <u>Cystic Fibrosis Foundation: 2000 North American CF Conference</u> , (November 2000),1-2	✓
DS		HSU, A., et al., "Ritonavir. Clinical pharmacokinetics and interactions with other	✓

EXAMINER

*DS*

DATE CONSIDERED

7/25/03

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1641
Examiner Name	Sullivan, Daniel

Sheet 4 of 6

Attorney Docket No: 875.032US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		anti-HIV agents", <u>Clin Pharmacokinetics</u> , 35(6), abstract, (December 1998), 1 page	
AS		HUANG, L., et al., "Efficient lipofection with cisplatin-resistant human tumor cells", <u>Cancer Gene Therapy</u> , vol. 3, no. 2, (1996), 107-112	✓
AS		IQBAL, MOHAMED, et al., "Potent Inhibitors of Proteasome", <u>Journal of Medicinal Chemistry</u> , vol. 38, no. 13, (1995), 2276-2277	✓
AS		KIM, KYUNG BO, et al., "Proteasome Inhibition by the Natural Products Epoxomicin and Dihydroeponepymycin: Insights into Specificity and Potency", <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , (1999), 3335-3340	✓
AS		LEE, SANG GOO, et al., "Enhancement of adenoviral transduction with polycationic liposomes in vivo", <u>Cancer Gene Therapy</u> , vol. 7, no. 10, (2000), 1329-1335	✓
AS		LEE, D. H., "Proteasome Inhibitors: Valuable New Tools For Cell Biologists", <u>Trends in Cell Biology</u> , 8, (October 1998), pp. 397-403	✓
AS		LEE, DO HEE, et al., "Selective Inhibitors of the Proteasome-dependent and Vacuolar Pathways of Protein Degradation in <i>Saccharomyces cerevisiae</i> ", <u>Journal of Biological Chemistry</u> , (November 1, 1996), 27280-27284	✓
AS		LEE, DO HEE, et al., "The Proteasome Inhibitors and Their Uses", <u>Proteasomes: The World of Regulatory Proteolysis</u> , (2000), 154-175	✓
AS		LU, WEI, et al., "HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism", <u>Blood</u> , vol. 96, no. 1, (July 1, 2000), 250-258	✓
AS		LUO, HONGYU, et al., "A Proteasome Inhibitor Effectively Prevents Mouse Heart Allograft Rejection", <u>Transplantation</u> , vol. 72, no. 2, (July 27, 2001), 196-202	✓
AS		MASTROIANNI, CLAUDIO M., et al., "Ex Vivo and In Vitro Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Apoptosis", <u>Journal of Infectious Diseases</u> (182), (November 2000), 1536-1539	✓
AS		MENG, LIHAO, et al., "Eponemycin Exerts Its Antitumor Effect through the Inhibition of Proteasome Function", <u>Cancer Research</u> , vol. 59, (June 15, 1999), 2798-2801	✓
AS		MENG, LIHAO, et al., "Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity", <u>Proc. National Academy of Science USA</u> , (August 1999), 10403-10408	✓
AS		MEYER, STEPHANIE, et al., "Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kB activation", <u>Federation of European Biochemical Societies</u> , (1997), 354-358	✓
AS		MOSNAIM, ARON, et al., "Degradation Kinetics of Leucine5-Enkephalin by Plasma Samples from Healthy Controls and Various Patient Populations: In Vitro Drug Effects", <u>American Journal of Therapeutics</u> , vol. 7, (2000), 185-194	✓
AS		NAM, SANGKIL, et al., "Tannic Acid Potently Inhibits Tumor Cell Proteasome Activity, Increases p27 and Bax Expression, and Induces G1 Arrest and	✓

EXAMINER

Sullivan

DATE CONSIDERED

7/25/03

Substitute Disclosure Statement Form (PTO-1449)


\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/689,136
Filing Date	October 12, 2000
First Named Inventor	Engelhardt, John
Group Art Unit	1641
Examiner Name	Sullivan, Daniel

Sheet 5 of 6

Attorney Docket No: 875.032US1

**OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Apoptosis", <u>Cancer Epidemiology, Biomarkers &amp; Prevention</u> , vol. 10, (October 2001),1083-1088	
DS		NEPKA, CHARITINI, et al., "Chemopreventive activity of very low dose dietary tannic acid administration in hepatoma bearing C3H male mice", <u>Cancer Letters</u> , vol. 141, (1999),57-62	✓
DS		NEPKA, CH., et al., "Tannins, xenobiotic metabolism and cancer chemo-prevention in experimental animals", <u>European Journal of Drug Metabolism and Pharmacokinetics</u> , vol. 24, no. 2, (1999),183-189	✓
DS		PALOMBELLA, VITO, et al., "Role of the proteasome and NF-kB in streptococcal cell wall-induced polyarthritis", <u>Proc. National Academy of Science USA</u> , vol. 95, (December 1998),15671-15676	✓
DS		PETROV, VICTOR, et al., "Effect of Protease Inhibitors on Angiotensin-Converting Enzyme Activity in Human T-Lymphocytes", <u>American Journal of Hypertension</u> , vol. 13, no. 5, (May 2000),535-539	✓
DS		RAO, SHARMILA, et al., "Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase", <u>Proc. National Academy of Science USA</u> , vol. 96, (July 1999),7797-7802	✓
DS		SCHWARTZ, DONALD, et al., "The neutral cysteine protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance", <u>Proc. National Academy of Science USA</u> , vol. 96, (April 1999),4680-4685	✓
DS		SCHWARZ, KATRIN, et al., "The Selective Proteasome Inhibitors Lactacystin and Epoxomicin can be used to either Up- or Down-Regulate Antigen Presentation at Nontoxic Doses", <u>Journal of Immunology</u> , (2000),6147-6157	✓
DS		SHAH, SHIMUL, et al., "26S Proteasome Inhibition Induces Apoptosis and Limits Growth of Human Pancreatic Cancer", <u>Journal of Cellular Biochemistry</u> , vol. 82, (2001),110-122	✓
DS		SMITH, H., et al., "Effect of a cancer cachectic factor on protein synthesis/degradation in murine C2C12 myoblasts: modulation by eicosapentaenoic acid", <u>Cancer Res.</u> , 59(21), abstract,(November 1999),1 page	
DS		SON, KYONGHEE, et al., "Exposure of human ovarian carcinoma to cisplatin transiently sensitizes the tumor cells for liposome-mediated gene transfer", <u>Proc. National Academy of Science USA</u> , vol. 91, (December 1994),12669-12672	✓
DS		SON, K, et al., "Factors influencing the drug sensitization of human tumor cells for in situ lipofection", <u>Gene Therapy</u> (3), (1996),630-634	✓
DS		SON, KYONGHEE, et al., "Nitric oxide-mediated tumor cell killing of cisplatin-based interferon-γ gene therapy in murine ovarian carcinoma", <u>Cancer Gene Therapy</u> , vol. 7, no. 10, (2000),1324-1328	✓
DS		TEODORI, L., et al., "Reduction of 1-beta-D-arabinofuranosylcytosine and adriamycin cytotoxicity following cell cycle arrest by anguidine", <u>Cancer Res.</u> , 41(4), abstract,(April 1981),1 page	✓
DS		TWEEDALE, TONY, "[Dioxin-I] Inhibits Estrogen-Induced Breast Cancer Cell	✓

EXAMINER

*DS*


DATE CONSIDERED

7/25/03

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional) <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Complete if Known	
		<b>Application Number</b>	09/689,136
		<b>Filing Date</b>	October 12, 2000
		<b>First Named Inventor</b>	Engelhardt, John
		<b>Group Art Unit</b>	1641
		<b>Examiner Name</b>	Sullivan, Daniel
Sheet 6 of 6		Attorney Docket No: 875.032US1	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
PS		Proliferation", <u>Reuters Health</u> , <a href="http://lists.essential.org/pipermail/dioxin-l/Week-of-Mon-2000103/000096.html">http://lists.essential.org/pipermail/dioxin-l/Week-of-Mon-2000103/000096.html</a> , (December 1999), 1 page	
PS		WOESSNER, RICHARD , et al., "Comparison of Three Approaches to Doxorubicin Therapy: Free Doxorubicin, Liposomal Doxorubicin, and B- Glucuronidase-Activated Prodrug (HMR 1826)", <u>Anticancer Research</u> , (2000),2289-2296	✓
PS		WOJCIK, CEZARY , et al., "Lovastatin and simvastatin are modulators of the proteasome", <u>International Journal of Biochemistry &amp; Cell Biology</u> , (32), (2000),957-965	✓
PS		WORKING, PETER , et al., "Pharmacological-Toxicological Expert Report (Stealth Liposomal Doxorubicin HCl)", <u>Human &amp; Experimental Toxicology</u> , (1996),752-785	✓

EXAMINER

*DSullivan*

DATE CONSIDERED 7/25/03